Skip to main content

Table 4 Results from multivariable logistic regression models for Q1–Q6, Q18–Q19

From: Patient consent preferences on sharing personal health information during the COVID-19 pandemic: “the more informed we are, the more likely we are to help”

Question

Outcome

Covariate

Level

OR

95% CI

p value

Q1: Your health information is divided into several different sections (e.g. diagnoses test results and images such as x-rays or scans). Would you like to:

1 = share all information; 0 = share some information

Cohort

Pandemic versus pre-pandemic

1.71

(0.87, 3.36)

0.12

Age group

50–74 versus 75+

1.26

(0.51, 3.10)

0.61

Age group

< 49 versus 75+

0.92

(0.30, 2.76)

0.88

Sex

Female versus male

0.27

(0.13, 0.56)

0.0004

Treatment phase

Follow-up versus treatment

1.25

(0.64, 2.43)

0.52

Treatment phase

Pre-treatment versus treatment

2.1

(0.44, 9.97)

0.35

Education

Post-sec. versus no/incomplete post-sec

0.84

(0.40, 1.79)

0.66

Q2: Your biological samples are classified into several different types (e.g. blood urine tissues). Would you like to:

1 = share all information; 0 = share some information

Cohort

Pandemic versus pre-pandemic

2.11

(1.03, 4.34)

0.042

Age group

50–74 versus 75+

1.33

(0.51, 3.46)

0.56

Age group

< 49 versus 75+

1.09

(0.34, 3.49)

0.89

Sex

Female versus male

0.28

(0.13, 0.60)

0.0011

Treatment phase

Follow-up versus treatment

1.27

(0.63, 2.54)

0.50

Treatment phase

Pre-treatment versus treatment

3.97

(0.49, 32.12)

0.20

Education

Post-sec. versus no/incomplete post-sec

0.55

(0.23, 1.30)

0.17

Q3: There are many different areas of medical research (e.g. research on cancer diabetes reproductive disorders genetic disorders heart disease etc.). Would you like to:

1 = share all information; 0 = share some information

Cohort

Pandemic versus pre-pandemic

1.84

(0.97, 3.48)

0.062

Age group

50–74 versus 75+

0.69

(0.26, 1.81)

0.45

Age group

< 49 versus 75+

0.57

(0.18, 1.77)

0.33

Sex

Female versus male

0.22

(0.11, 0.44)

 < .0001

Treatment phase

Follow-up versus treatment

0.98

(0.53, 1.83)

0.95

Treatment phase

Pre-treatment versus treatment

2.07

(0.44, 9.79)

0.36

Education

Post-sec. versus no/incomplete post-sec

0.7

(0.33, 1.46)

0.34

Q4: When asked for consent to share your information or samples would you like to have an option to think about the decision and be asked again later?

1 = option to re-consider; 0 = no option to re-consider

Cohort

Pandemic versus pre-pandemic

0.85

(0.56, 1.28)

0.43

Age group

50–74 versus 75+

1.64

(0.94, 2.87)

0.083

Age group

< 49 versus 75+

2.28

(1.08, 4.81)

0.0307

Sex

Female versus male

1.05

(0.69, 1.58)

0.83

Treatment phase

Follow-up versus treatment

1.16

(0.76, 1.78)

0.48

Treatment phase

Pre-treatment versus treatment

1.32

(0.60, 2.92)

0.49

Education

Post-Sec. versus no/incomplete post-sec

0.87

(0.55, 1.36)

0.53

Q5: Your health information and samples are often requested for future studies. Would you like to:

1 = broad consent; 0 = study-specific consent

Cohort

Pandemic versus pre-pandemic

0.78

(0.50, 1.21)

0.27

Age group

50–74 versus 75+

0.61

(0.34, 1.12)

0.11

Age group

< 49 versus 75+

0.43

(0.20, 0.95)

0.0366

Sex

Female versus male

0.55

(0.36, 0.85)

0.0068

Treatment phase

Follow-up versus treatment

0.84

(0.54, 1.31)

0.45

Treatment phase

Pre-treatment versus treatment

1.19

(0.49, 2.90)

0.70

Education

Post-sec. versus no/incomplete post-sec

1.18

(0.73, 1.90)

0.51

Q6: A contact pool may be created with patient names phone numbers and key pieces of health information. UHN Researchers with ethical approval for their studies could search this pool to find participants. Would you prefer to be:

1 = automatically entered into a contact pool; 0 = asked for permission

Cohort

Pandemic versus pre-pandemic

1.12

(0.73, 1.72)

0.60

Age group

50–74 versus 75+

0.75

(0.42, 1.32)

0.32

Age group

< 49 versus 75+

0.59

(0.27, 1.27)

0.18

Sex

Female versus male

0.74

(0.49, 1.14)

0.17

Treatment phase

Follow-up versus treatment

0.84

(0.55, 1.31)

0.45

Treatment phase

Pre-treatment versus treatment

0.97

(0.42, 2.26)

0.95

Education

Post-sec. versus no/incomplete post-sec

1.76

(1.09, 2.85)

0.0204

Q18: Would you like to be able to track who is using your information or samples and what they are using it for?

1 = wanting to track information/sample use; 0 = not wanting to track information/sample use

Cohort

Pandemic versus pre-pandemic

1.89

(1.18, 3.03)

0.0079

Age group

50–74 versus 75+

1.98

(1.12, 3.51)

0.0185

Age group

< 49 versus 75+

2.68

(1.15, 6.26)

0.0223

Sex

Female versus male

1.12

(0.71, 1.78)

0.61

Treatment phase

Follow-up versus treatment

1.61

(1.00, 2.61)

0.0498

Treatment phase

Pre-treatment versus treatment

1.3

(0.54, 3.13)

0.55

Education

Post-sec. versus no/incomplete post-sec

1.18

(0.72, 1.94)

0.50

Q19: Would you like to be notified with the results of studies that have used your information or samples?

1 = wanting to be notified of study results; 0 = not wanting to be notified of study results

Cohort

Pandemic versus pre-pandemic

2.06

(1.21, 3.51)

0.0082

Age group

50–74 versus 75+

1.56

(0.84, 2.88)

0.16

Age group

< 49 versus 75+

2.67

(0.99, 7.22)

0.053

Sex

Female versus male

1.16

(0.70, 1.94)

0.56

Treatment phase

Follow-up versus treatment

1.59

(0.93, 2.72)

0.092

Treatment phase

Pre-treatment versus treatment

0.84

(0.34, 2.08)

0.70

Education

Post-sec. versus no/incomplete post-sec

1.02

(0.59, 1.76)

0.95

  1. The outcome column outlines how the outcome was coded for each question